Evidence map›Paper›PMID 39548698›Full record

ArticleAutism research : official journal of the International Society for Autism Research2025

Detailed phenotyping of Tbr1-2A-CreER knock-in mice demonstrates significant impacts on TBR1 protein levels and axon development.

Marissa Co, Grace K O'Brien, Kevin M Wright, Brian J O'Roak

Abstract read
In one paragraph

Article in Autism research : official journal of the International Society for Autism Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Marissa CoDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.ORCID 0000-0002-6764-0171
Grace K O'BrienDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.
Kevin M WrightVollum Institute, Oregon Health & Science University, Portland, Oregon, USA.
Brian J O'RoakDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.

Funding

Oregon Clinical and Translational Research Institute TL1 ProgramTL1TR002371 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI ALLISON Deborah FRYER, JESSINA C MCGREGOR · 2017 to 2026
$6.2M
Characterizing patient-specific TBR1 mutations: Understanding a master regulator of autism risk.R01MH113926 · NIMH · OREGON HEALTH & SCIENCE UNIVERSITY · PI Brian James O'Roak · 2017 to 2026
$3.5M
Collins Medical TrustMRF 003835MRF_ 003835NCATS NIH HHS TL1 TR002371NCATS NIH HHS TL1TR002371NIMH NIH HHS R01 MH113926NIMH NIH HHS R01MH113926OHSU Brain Institute Neuroscience Campaign Fund to Support Brain Health Across the Lifespan 005229OHSU Richard & Marilyn Jones Endowed Fund for Advancement in Autism Research
6 · The paper itself

Abstract

Cre recombinase knock-in mouse lines have served as invaluable genetic tools for understanding key developmental processes altered in autism. However, insertion of exogenous DNA into the genome can have unintended effects on local gene regulation or protein function that must be carefully considered. Here, we analyze a recently generated Tbr1-2A-CreER knock-in mouse line, where a 2A-CreER cassette was inserted in-frame before the stop codon of the transcription factor gene Tbr1. Heterozygous TBR1 mutations in humans and mice are known to cause autism or autism-like behavioral phenotypes accompanied by structural brain malformations, most frequently a reduction of the anterior commissure (AC). Thus, it is critical for modified versions of Tbr1 to exhibit true wild-type-like activity. We evaluated the Tbr1-2A-CreER allele for its potential impact on Tbr1 function and complementation to Tbr1 loss-of-function alleles. In mice with one copy of the Tbr1-2A-CreER allele, we identified reduction of TBR1 protein in early postnatal cortex along with thinning of the AC, suggesting hypersensitivity of this structure to TBR1 dosage. Comparing Tbr1-2A-CreER and Tbr1-null mice to Tbr1-null complementation crosses showed reductions of TBR1 dosage ranging from 20% to 100%. Using six combinatorial genotypes, we found that moderate to severe TBR1 reductions (≥44%) were associated with cortical layer 5 expansion, while only the complete absence of TBR1 was associated with reeler-like "inverted" cortical layering. In total, these results strongly support the conclusion that Tbr1-2A-CreER is a hypomorphic allele. We advise caution when interpreting experiments using this allele, considering the sensitivity of various corticogenic processes to TBR1 dosage and the association of heterozygous TBR1 mutations with complex neurodevelopmental disorders.

Indexed as

AxonsDNA-Binding ProteinsAnimalsBrainDisease Models, AnimalGene Knock-In TechniquesMiceMice, TransgenicPhenotypeT-Box Domain ProteinsDNA-Binding ProteinsT-Box Domain ProteinsTbr1 protein, mouseanterior commissureaxoncortexmiceTBR1transcription factor

Identifiers

PMID39548698
PMCPMC12078632

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.